FDA’s vacation from an elevated level of new ANDA submissions continued through the start of 2015, but so far it has not translated into a dramatic increase in approvals.
Generic sponsors still may be recovering from their massive push to get submissions to the agency last summer ahead of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?